242 related articles for article (PubMed ID: 16001982)
41. Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC.
Munster P; Marchion D; Bicaku E; Lacevic M; Kim J; Centeno B; Daud A; Neuger A; Minton S; Sullivan D
Clin Cancer Res; 2009 Apr; 15(7):2488-96. PubMed ID: 19318486
[TBL] [Abstract][Full Text] [Related]
42. Aberrant histone modification in peripheral blood B cells from patients with systemic sclerosis.
Wang Y; Yang Y; Luo Y; Yin Y; Wang Q; Li Y; Kanekura T; Wang J; Liang G; Zhao M; Lu Q; Xiao R
Clin Immunol; 2013 Oct; 149(1):46-54. PubMed ID: 23891737
[TBL] [Abstract][Full Text] [Related]
43. Acetylation: a lysine modification with neuroprotective effects in ischemic retinal degeneration.
Alsarraf O; Fan J; Dahrouj M; Chou CJ; Menick DR; Crosson CE
Exp Eye Res; 2014 Oct; 127():124-31. PubMed ID: 25064603
[TBL] [Abstract][Full Text] [Related]
44. The chemopreventive activity of the butyric acid prodrug tributyrin in experimental rat hepatocarcinogenesis is associated with p53 acetylation and activation of the p53 apoptotic signaling pathway.
de Conti A; Tryndyak V; Koturbash I; Heidor R; Kuroiwa-Trzmielina J; Ong TP; Beland FA; Moreno FS; Pogribny IP
Carcinogenesis; 2013 Aug; 34(8):1900-6. PubMed ID: 23568954
[TBL] [Abstract][Full Text] [Related]
45. Epigenetic evidence of an Ac/Dc axis by VPA and SAHA.
Lunke S; Maxwell S; Khurana I; K N H; Okabe J; Al-Hasani K; El-Osta A
Clin Epigenetics; 2021 Mar; 13(1):58. PubMed ID: 33743782
[TBL] [Abstract][Full Text] [Related]
46. L- and D-lactate enhance DNA repair and modulate the resistance of cervical carcinoma cells to anticancer drugs via histone deacetylase inhibition and hydroxycarboxylic acid receptor 1 activation.
Wagner W; Ciszewski WM; Kania KD
Cell Commun Signal; 2015 Jul; 13():36. PubMed ID: 26208712
[TBL] [Abstract][Full Text] [Related]
47. Cross-communication between histone H3 and H4 acetylation and Akt-mTOR signalling in prostate cancer cells.
Makarević J; Tawanaie N; Juengel E; Reiter M; Mani J; Tsaur I; Bartsch G; Haferkamp A; Blaheta RA
J Cell Mol Med; 2014 Jul; 18(7):1460-6. PubMed ID: 24779401
[TBL] [Abstract][Full Text] [Related]
48. [Gender-dependent effects of histone deacetylase inhibitor sodium valproate on early olfactory learning in 129Sv mice].
Burenkova OV; Aleksandrova EA; Zaraĭskaia IIu
Ross Fiziol Zh Im I M Sechenova; 2013 Feb; 99(2):212-20. PubMed ID: 23650734
[TBL] [Abstract][Full Text] [Related]
49. Inhibition of histone deacetylase in utero causes sociability deficits in postnatal mice.
Moldrich RX; Leanage G; She D; Dolan-Evans E; Nelson M; Reza N; Reutens DC
Behav Brain Res; 2013 Nov; 257():253-64. PubMed ID: 24103642
[TBL] [Abstract][Full Text] [Related]
50. An ELISA method to assess HDAC inhibitor-induced alterations to P. falciparum histone lysine acetylation.
Hesping E; Skinner-Adams TS; Fisher GM; Kurz T; Andrews KT
Int J Parasitol Drugs Drug Resist; 2020 Dec; 14():249-256. PubMed ID: 33279862
[TBL] [Abstract][Full Text] [Related]
51. Acetate supplementation increases brain histone acetylation and inhibits histone deacetylase activity and expression.
Soliman ML; Rosenberger TA
Mol Cell Biochem; 2011 Jun; 352(1-2):173-80. PubMed ID: 21359531
[TBL] [Abstract][Full Text] [Related]
52. Cell differentiation along multiple pathways accompanied by changes in histone acetylation status.
Legartová S; Kozubek S; Franek M; Zdráhal Z; Lochmanová G; Martinet N; Bártová E
Biochem Cell Biol; 2014 Apr; 92(2):85-93. PubMed ID: 24697692
[TBL] [Abstract][Full Text] [Related]
53. Valproic acid induces growth arrest, apoptosis, and senescence in medulloblastomas by increasing histone hyperacetylation and regulating expression of p21Cip1, CDK4, and CMYC.
Li XN; Shu Q; Su JM; Perlaky L; Blaney SM; Lau CC
Mol Cancer Ther; 2005 Dec; 4(12):1912-22. PubMed ID: 16373706
[TBL] [Abstract][Full Text] [Related]
54. Binding mode analysis of 3-(4-benzoyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-propenamide: a new synthetic histone deacetylase inhibitor inducing histone hyperacetylation, growth inhibition, and terminal cell differentiation.
Mai A; Massa S; Ragno R; Esposito M; Sbardella G; Nocca G; Scatena R; Jesacher F; Loidl P; Brosch G
J Med Chem; 2002 Apr; 45(9):1778-84. PubMed ID: 11960489
[TBL] [Abstract][Full Text] [Related]
55. Effects of histone deacetylase inhibitors on regenerative cell responses in human dental pulp cells.
Luo Z; Wang Z; He X; Liu N; Liu B; Sun L; Wang J; Ma F; Duncan H; He W; Cooper P
Int Endod J; 2018 Jul; 51(7):767-778. PubMed ID: 28375564
[TBL] [Abstract][Full Text] [Related]
56. Inhibition of histone deacetylation: a strategy for tumor radiosensitization.
Camphausen K; Tofilon PJ
J Clin Oncol; 2007 Sep; 25(26):4051-6. PubMed ID: 17827453
[TBL] [Abstract][Full Text] [Related]
57. Sodium propionate and sodium butyrate effects on histone deacetylase (HDAC) activity, histone acetylation, and inflammatory gene expression in bovine mammary epithelial cells.
Silva LG; Ferguson BS; Avila AS; Faciola AP
J Anim Sci; 2018 Dec; 96(12):5244-5252. PubMed ID: 30252114
[TBL] [Abstract][Full Text] [Related]
58. The antiepileptic and anticancer agent, valproic acid, induces P-glycoprotein in human tumour cell lines and in rat liver.
Eyal S; Lamb JG; Smith-Yockman M; Yagen B; Fibach E; Altschuler Y; White HS; Bialer M
Br J Pharmacol; 2006 Oct; 149(3):250-60. PubMed ID: 16894351
[TBL] [Abstract][Full Text] [Related]
59. Valproate increases dopamine transporter expression through histone acetylation and enhanced promoter binding of Nurr1.
Green AL; Zhan L; Eid A; Zarbl H; Guo GL; Richardson JR
Neuropharmacology; 2017 Oct; 125():189-196. PubMed ID: 28743636
[TBL] [Abstract][Full Text] [Related]
60. Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.
Caponigro F; Di Gennaro E; Ionna F; Longo F; Aversa C; Pavone E; Maglione MG; Di Marzo M; Muto P; Cavalcanti E; Petrillo A; Sandomenico F; Maiolino P; D'Aniello R; Botti G; De Cecio R; Losito NS; Scala S; Trotta A; Zotti AI; Bruzzese F; Daponte A; Calogero E; Montano M; Pontone M; De Feo G; Perri F; Budillon A
BMC Cancer; 2016 Nov; 16(1):918. PubMed ID: 27884140
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
